.jpg)
.png)
All
Clinical Case The patient is a 67-year-old white gentleman with type 2 diabetes mellitus (T2DM), hypertension (HTN), 20-pack-year smoking history, and dyslipidemia. He presented to the Lipidology Clinic for a follow-up of his diabetes and atherogenic dyslipidemia. He has never experienced any... more
Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and... more
There are many new influences on how dyslipidemia is managed today. While this is exciting, as is common with change, there are cogs in the wheel of progress. Healthcare providers and patients are aware of barriers for implementing therapies that appear to be efficacious for optimal care. Multiple... more
Statin-associated muscle symptoms (SAMS) are the most common form of statin intolerance and are associated with increased risk of cardiovascular events that manifest from statin underutilization and discontinuation. Treatment to reduce low-density lipoprotein cholesterol (LDL-C) and other... more
Dr. Soffer: Greetings from Philadelphia. Dr. Saseen and I are very excited to be the new editors of the LipidSpin. Like many of you, I am a long-time reader and occasional contributor, and I consider it a great honor to be entrusted with this responsibility. As the editors, Joe and I are... more
It is an honor and a privilege to serve as the President of the Southeast Lipid Association (SELA) for the next 12 months. I can only hope to emulate the energy, enthusiasm, and leadership skills of those persons preceding me. But also, I would like to bring a fresh perspective as a full-time... more
.field.field-name-field-embargo.field-type-datetime.field-label-hidden, .field.field-name-field-rating.field-type-fivestar.field-label-inline.clearfix, .links { display: none } .body_table li, .head_table li, .body_table p, .head_table p { line-height: 20px; } .body_table a, .... more
What will it take to lower your patient’s risk of heart attack and stroke? Can we improve on previous risk prediction tools? Can we address global cardiovascular disease risk better in women and African Americans? Can we initiate atherosclerotic cardiovascular disease (ASCVD) risk reduction... more
Q: Why do you support DE and I for NLA? In general terms, I am a very strong supporter of DEI as a core foundational principle for all organizations. Specifically, for the NLA, integration of DEI is critical to ensure that the vision, mission, and goals for the organization are reflective of the... more